From dry eye to GLP-1s, this year's conference brought a variety of insights from key experts in optometry.
|Articles|July 20, 2020
- July digital edition 2020
- Volume 12
- Issue 07
July 2020: Best of Q&A
Author(s)Brooke Henson, Editor
Check out our latest Q&As from July 2020
Advertisement
Articles in this issue
over 5 years ago
How one OD encouraged glaucoma medication adherenceabout 6 years ago
What to do if you're hit with tear gasover 6 years ago
Light versus wellness: a modern dilemmaover 6 years ago
COVID-19 response brings new protocolsover 6 years ago
MITA Eyewear debuts stylesover 6 years ago
12 recommendations for prescribing opioidsover 6 years ago
3 steps to getting started with dry eye treatmentover 6 years ago
The dropless future: SLT as a first-line treatment for glaucomaover 6 years ago
Committed to safety: One OD’s COVID-19 responseAdvertisement
Related to this article
Presenters from AAOpt26's research symposium share their findings, applications for optometric practice, and goals for future study.
For Maria Sampalis, OD, implementing AI isn't an excuse for practice owners to replace their staff with new technology; it should instead lift the burden of certain tasks to make for more patient visits.
Walline, American Academy of Optometry president, shares this year's conference attendance numbers, clinical pearls, and what he hopes to see in 2027.
Thomas Wong, OD, FAAO, details a session he presented alongside Ronald Gentile, MD, FACS, FASRS, at AAOpt 2026.
Kevin Chan, OD, MS, discusses an AAOpt 2026 symposium on individualized low-dose atropine dosing for myopia and the FDA outlook ahead of the SYD-101 advisory meeting.
Raman Bhakhri, OD, FAAO, alongside Xiao Yu, OD, FAAO, discussed emerging investigational therapies for the disease during their AAOpt 2026 session.
Jamie Kuzniar, OD, FAAO, FSLS, discusses a case-based AAOpt 2026 session on scleral lens complications, fitting around cross-linking, and advice for new graduates.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
FDA approves phentolamine ophthalmic solution 0.75% (Ryzumvi) for presbyopia
2
FDA approves Brytly eye drops for ocular redness relief lasting up to 12 hours
3
Missed AAOpt 2026? Here are the highlights by specialty
4
FDA approves subcutaneous Enspryng for TED
5